Jpmorgan Chase & CO Nuvation Bio Inc. Put Options Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding NUVB
# of Institutions
159Shares Held
157MCall Options Held
3.2KPut Options Held
98.7K-
Decheng Capital LLC Menlo Park, CA26MShares$72.7 Million14.08% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA19.2MShares$53.8 Million1.92% of portfolio
-
Black Rock Inc. New York, NY16.2MShares$45.5 Million0.0% of portfolio
-
Omega Fund Management, LLC Boston, MA13.1MShares$36.6 Million44.61% of portfolio
-
Octagon Capital Advisors LP New York, NY12.2MShares$34.1 Million6.76% of portfolio
About Nuvation Bio Inc.
- Ticker NUVB
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 217,244,000
- Market Cap $608M
- Description
- Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...